The initial public offering (IPO) of Rubicon Research Ltd. received a promising response on its opening day, achieving 51% subscription. Backed by strong interest from retail investors, the issue marks a confident debut for the pharmaceutical formulation development company in India’s bustling capital market. The IPO, comprising both fresh equity and an offer for sale, aims to strengthen Rubicon’s balance sheet and support its growth initiatives. Early market data indicates moderate participation from institutional investors, with retail demand emerging as the key growth driver.